<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">41023853</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2261</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>29</Day></PubDate></JournalIssue><Title>BMC cardiovascular disorders</Title><ISOAbbreviation>BMC Cardiovasc Disord</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.</ArticleTitle><Pagination><StartPage>701</StartPage><MedlinePgn>701</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12872-025-05098-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mineralocorticoid receptor antagonists (MRAs) are established for heart failure with reduced ejection fraction (HFrEF), but their benefits in mildly reduced/preserved EF (HFmrEF/HFpEF) and agent-specific profiles require clarification. This meta-analysis aimed to evaluate the efficacy, safety, and benefit-risk profiles of MRAs across heart failure phenotypes and agents.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This meta-analysis synthesized data from randomized controlled trials (RCTs). The primary outcome was a composite of hospitalization for heart failure (HHF) or cardiovascular death. Secondary outcomes included HHF, cardiovascular/all-cause mortality, and safety endpoints. Subgroup analyses examined heart failure phenotypes and MRA agents. Benefit-risk was quantified via Number Needed to Treat/Harm (NNT/NNH).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Data from six RCTs (FINEARTS-HF, EPHESUS, EMPHASIS-HF, J-EMPHASIS-HF, TOPCAT, RALES; n&#x2009;=&#x2009;20,699) were synthesized. MRAs significantly reduced the primary composite outcome (HR&#x2009;=&#x2009;0.79, 95% CI 0.71-0.88; P&#x2009;&lt;&#x2009;0.001; NNT<sub>2.24yr</sub> =22.4), with consistent effects across demographic subgroups. Reductions were also observed in cardiovascular mortality (HR&#x2009;=&#x2009;0.82, NNT<sub>2.24yr</sub> = 45.5), sudden cardiac death (HR&#x2009;=&#x2009;0.78, NNT<sub>2.24yr</sub> = 67), HHF (HR&#x2009;=&#x2009;0.76, NNT<sub>2.24yr</sub> = 25), and all-cause mortality (HR&#x2009;=&#x2009;0.84, NNT<sub>2.24yr</sub> = 39.1). Safety analyses revealed increased risks of hyperkalemia (K&#x207a; &gt;5.5 mmol/L: OR&#x2009;=&#x2009;2.29, NNH<sub>2.24yr</sub> = 12.7), hypotension (OR&#x2009;=&#x2009;1.52, NNH<sub>2.24yr</sub> = 23.3), and renal impairment (creatinine&#x2009;&#x2265;&#x2009;2.5&#xa0;mg/dL: OR&#x2009;=&#x2009;1.63, NNH<sub>2.24yr</sub> = 49.2), alongside a decreased risk of hypokalemia (K&#x207a; &lt; 3.5 mmol/L: OR&#x2009;=&#x2009;0.52, NNT<sub>2.24yr</sub> = 17.3). Subgroup analyses demonstrated significant mortality benefits in HFrEF (cardiovascular mortality HR&#x2009;=&#x2009;0.77; all-cause mortality HR&#x2009;=&#x2009;0.78), although hospitalization benefits extended to both HFrEF and HFmrEF/HFpEF. Eplerenone demonstrated significant mortality reduction (cardiovascular mortality HR&#x2009;=&#x2009;0.81; all-cause mortality HR&#x2009;=&#x2009;0.83), while spironolactone only showed significant HHF reduction (HR&#x2009;=&#x2009;0.73).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">MRAs significantly reduce composite cardiovascular outcomes across heart failure phenotypes, with mortality benefits predominantly in HFrEF. Eplerenone appears to offer stronger mortality advantages, while spironolactone is more effective in reducing hospitalizations. These findings support phenotype- and agent-specific strategies to optimize the benefit-risk profile of MRA therapy in heart failure.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jinfei</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Yingtan Hospital of Traditional Chinese Medicine, Yingtan City, Jiangxi Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pei</LastName><ForeName>Yibin</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Anqing 116 Hospital, Anqing City, Anhui Province, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Yingtan 184 Hospital, NO.4, Hudong Road, Yuehu District, Yingtan City, Jiangxi Province, 335000, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yongfang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Yingtan 184 Hospital, NO.4, Hudong Road, Yuehu District, Yingtan City, Jiangxi Province, 335000, China. yongfanghuang2506@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Cardiovasc Disord</MedlineTA><NlmUniqueID>100968539</NlmUniqueID><ISSNLinking>1471-2261</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000451" MajorTopicYN="Y">Mineralocorticoid Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006947" MajorTopicYN="N">Hyperkalemia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016277" MajorTopicYN="Y">Ventricular Function, Left</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002423" MajorTopicYN="N">Cause of Death</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Eplerenone</Keyword><Keyword MajorTopicYN="N">Finerenone</Keyword><Keyword MajorTopicYN="N">Heart failure with preserved ejection fraction</Keyword><Keyword MajorTopicYN="N">Heart failure with reduced ejection fraction</Keyword><Keyword MajorTopicYN="N">Mineralocorticoid receptor antagonists</Keyword><Keyword MajorTopicYN="N">Number needed to treat</Keyword><Keyword MajorTopicYN="N">Spironolactone</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>6</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>30</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">41023853</ArticleId><ArticleId IdType="doi">10.1186/s12872-025-05098-5</ArticleId><ArticleId IdType="pii">10.1186/s12872-025-05098-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">32483830</ArticleId><ArticleId IdType="doi">10.1002/ejhf.1858</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and writing committee of the universal definition of heart failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">33605000</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2115</ArticleId></ArticleIdList></Reference><Reference><Citation>Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation. 2022;145:e876-94.</Citation><ArticleIdList><ArticleId IdType="pubmed">35363500</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrera-Chimal J, Bonnard B, Jaisser F. Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases. Annu Rev Physiol. 2022;84:585&#x2013;610.</Citation><ArticleIdList><ArticleId IdType="pubmed">35143332</ArticleId><ArticleId IdType="doi">10.1146/annurev-physiol-060821-013950</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42:152&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">33099609</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaa736</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmas CE, Silverio D, Sourlas A, Montan PD, Guzman E. Role of spironolactone in the treatment of heart failure with preserved ejection fraction. Ann Transl Med. 2018;6:461.</Citation><ArticleIdList><ArticleId IdType="pubmed">30603649</ArticleId><ArticleId IdType="pmc">6312809</ArticleId><ArticleId IdType="doi">10.21037/atm.2018.11.16</ArticleId></ArticleIdList></Reference><Reference><Citation>Danjuma MI, Mukherjee I, Makaronidis J, Osula S. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles. Curr Hypertens Rep. 2014;16:414.</Citation><ArticleIdList><ArticleId IdType="pubmed">24407447</ArticleId><ArticleId IdType="doi">10.1007/s11906-013-0414-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Elshahat A, Mansour A, Ellabban M, Diaa A, Hassan A, Fawzy A, et al. Comparative effectiveness and safety of eplerenone and spironolactone in patients with heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord. 2024;24:489.</Citation><ArticleIdList><ArticleId IdType="pubmed">39271992</ArticleId><ArticleId IdType="pmc">11395778</ArticleId><ArticleId IdType="doi">10.1186/s12872-024-04103-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Obeid H, Chen Cardenas SM, Khairi S, Turcu AF. Personalized treatment of patients with primary aldosteronism. Endocr Pract. 2023;29:484&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">36273684</ArticleId><ArticleId IdType="doi">10.1016/j.eprac.2022.10.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kintscher U, Bakris GL, Kolkhof P. Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Br J Pharmacol. 2022;179:3220&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">34811750</ArticleId><ArticleId IdType="doi">10.1111/bph.15747</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhai S, Ma B, Chen W, Zhao Q. A comprehensive review of finerenone-a third-generation non-steroidal mineralocorticoid receptor antagonist. Front Cardiovasc Med. 2024;11:1476029.</Citation><ArticleIdList><ArticleId IdType="pubmed">39376623</ArticleId><ArticleId IdType="pmc">11456546</ArticleId><ArticleId IdType="doi">10.3389/fcvm.2024.1476029</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Randomized aldactone evaluation study investigators, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">10471456</ArticleId><ArticleId IdType="doi">10.1056/NEJM199909023411001</ArticleId></ArticleIdList></Reference><Reference><Citation>Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">21073363</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1009492</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y, Song M, Chen T, Yang Z, Liu Y. Effect of finerenone on cardiovascular events in kidney disease and/or diabetes: a meta analysis of randomized control trials. Int Urol Nephrol. 2023;55:1373&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">36571667</ArticleId><ArticleId IdType="doi">10.1007/s11255-022-03432-w</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2024;391:1475&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pubmed">39225278</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2407107</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716680</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1313731</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese G, Carrero JJ, Pitt B, Anker SD, Rosano GMC, Dahlstr&#xf6;m U, et al. Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish heart failure registry. Eur J Heart Fail. 2018;20:1326&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">29578280</ArticleId><ArticleId IdType="doi">10.1002/ejhf.1182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahir D, Bonde A, Madelaire C, Malmborg M, Butt JH, Fosbol E, et al. Temporal trends in initiation of mineralocorticoid receptor antagonists and risk of subsequent withdrawal in patients with heart failure: a nationwide study in Denmark from 2003&#x2013;2017. Eur J Heart Fail. 2022;24:539&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">34969178</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2418</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.</Citation><ArticleIdList><ArticleId IdType="pubmed">33782057</ArticleId><ArticleId IdType="pmc">8005924</ArticleId><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">12958120</ArticleId><ArticleId IdType="pmc">192859</ArticleId><ArticleId IdType="doi">10.1136/bmj.327.7414.557</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPTJ, Chandler J, Cumpston M, Li T, Page M. Cochrane handbook for systematic reviews of interventions. Altman DG, editor: Cochrane Training;: Deeks JJ HJ; 2024.</Citation></Reference><Reference><Citation>Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, et al. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation. 2015;131:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25406305</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.013255</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendes D, Alves C, Batel-Marques F. Number needed to treat (NNT) in clinical literature: an appraisal. BMC Med. 2017;15:112.</Citation><ArticleIdList><ArticleId IdType="pubmed">28571585</ArticleId><ArticleId IdType="pmc">5455127</ArticleId><ArticleId IdType="doi">10.1186/s12916-017-0875-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman DG, Andersen PK. Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999;319:1492&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">10582940</ArticleId><ArticleId IdType="pmc">1117211</ArticleId><ArticleId IdType="doi">10.1136/bmj.319.7223.1492</ArticleId></ArticleIdList></Reference><Reference><Citation>Briere JB, Bowrin K, Millier A, Toumi M, Wojciechowski P, Taieb V. Number needed to treat based on real-world evidence for non-vitamin K antagonist oral anticoagulants versus vitamin K antagonist oral anticoagulants in stroke prevention in patients with non-valvular atrial fibrillation. J Med Econ. 2019;22:760&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">30969801</ArticleId><ArticleId IdType="doi">10.1080/13696998.2019.1606001</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJHJ, Altman DG, McKenzie JE, Veroniki AA,Chapter 10: Chap. 10: Analysing data and undertaking meta-analyses [last updated November 2024]. In:, Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 65 Cochrane, 2024 Available from cochraneorg/handbook.</Citation></Reference><Reference><Citation>Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">12668699</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa030207</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, et al. Double-Blind, randomized, Placebo-Controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J. 2017;82:148&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">28824029</ArticleId><ArticleId IdType="doi">10.1253/circj.CJ-17-0323</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan LA, Jamil A, Greene SJ, Khan MS, Butler J. Aldosterone and potassium in heart failure: overcoming this major impediment in clinical practice. Card Fail Rev. 2024;10:e18.</Citation><ArticleIdList><ArticleId IdType="pubmed">39872850</ArticleId><ArticleId IdType="pmc">11770538</ArticleId><ArticleId IdType="doi">10.15420/cfr.2024.09</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai AS, Liu J, Pfeffer MA, Claggett B, Fleg J, Lewis EF, et al. Incident hyperkalemia, hypokalemia, and clinical outcomes during spironolactone treatment of heart failure with preserved ejection fraction: analysis of the TOPCAT trial. J Card Fail. 2018;24:313&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">29572190</ArticleId><ArticleId IdType="doi">10.1016/j.cardfail.2018.03.002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayyas F, Alzoubi KH, Van Wagoner DR. Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling. Int J Cardiol. 2013;168:5135&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">23993726</ArticleId><ArticleId IdType="pmc">4062912</ArticleId><ArticleId IdType="doi">10.1016/j.ijcard.2013.08.022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavall D, Selzer C, Schuster P, Lenski M, Adam O, Sch&#xe4;fers HJ, et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. J Biol Chem. 2014;289:6656&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">24469458</ArticleId><ArticleId IdType="pmc">3945327</ArticleId><ArticleId IdType="doi">10.1074/jbc.M113.519256</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy SP, Ibrahim NE, Januzzi JL Jr. Heart failure with reduced ejection fraction: a review. JAMA. 2020;324:488&#x2013;504.</Citation><ArticleIdList><ArticleId IdType="pubmed">32749493</ArticleId><ArticleId IdType="doi">10.1001/jama.2020.10262</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Henderson AD, Docherty KF, Jhund PS, Vaduganathan M, Solomon SD, et al. Why have we not been able to demonstrate reduced mortality in patients with HFrEF/HFpEF?? J Am Coll Cardiol. 2024;84:2233&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">39217560</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2024.08.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Naser N, Durak-Nalbantic A, Sabanovic-Bajramovic N, Karic A. The effectiveness of eplerenone vs spironolactone on left ventricular systolic function, hospitalization and cardiovascular death in patients with chronic heart failure-HFrEF. Med Arch. 2023;77:105&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">37260796</ArticleId><ArticleId IdType="pmc">10227849</ArticleId><ArticleId IdType="doi">10.5455/medarh.2023.77.105-111</ArticleId></ArticleIdList></Reference><Reference><Citation>Pardo-Mart&#xed;nez P, Barge-Caballero E, Bouzas-Mosquera A, Barge-Caballero G, Couto-Mall&#xf3;n D, Paniagua-Mart&#xed;n MJ, et al. Real world comparison of spironolactone and eplerenone in patients with heart failure. Eur J Intern Med. 2022;97:86&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">35000806</ArticleId><ArticleId IdType="doi">10.1016/j.ejim.2021.12.027</ArticleId></ArticleIdList></Reference><Reference><Citation>Vukadinovi&#x107; D, Lavall D, Vukadinovi&#x107; AN, Pitt B, Wagenpfeil S, B&#xf6;hm M. True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J. 2017;188:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">28577687</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2017.03.011</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23:1698&#x2013;707.</Citation><ArticleIdList><ArticleId IdType="pubmed">34196082</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2287</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira JP, Claggett BL, Liu J, Desai AS, Pfeffer MA, Anand IS, et al. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial. Eur J Heart Fail. 2021;23:776&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">33609066</ArticleId><ArticleId IdType="doi">10.1002/ejhf.2134</ArticleId></ArticleIdList></Reference><Reference><Citation>Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20:1217&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">29667759</ArticleId><ArticleId IdType="doi">10.1002/ejhf.1199</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaduganathan M, Filippatos G, Claggett BL, Desai AS, Jhund PS, Henderson A, et al. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nat Med. 2024;30:3758&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">39218030</ArticleId><ArticleId IdType="pmc">11645272</ArticleId><ArticleId IdType="doi">10.1038/s41591-024-03264-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Memon AAQ, Iqbal S. Finerenone, a novel and safer approach toward management of diabetic kidney disease with heart failure. Global J Medical, Pharmaceutical, and Biomedical Update. 2022;17:12.</Citation><ArticleIdList><ArticleId IdType="doi">10.25259/GJMPBU_25_2022</ArticleId></ArticleIdList></Reference><Reference><Citation>Ashjian E, Clarke M, Pogue K. Pharmacotherapy considerations with finerenone in the treatment of chronic kidney disease associated with type 2 diabetes. Am J Health-Syst Pharm. 2023;80:1708&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">37632460</ArticleId><ArticleId IdType="pmc">10664185</ArticleId><ArticleId IdType="doi">10.1093/ajhp/zxad192</ArticleId></ArticleIdList></Reference><Reference><Citation>Gudino Flores, Paola MD; Rodriguez Salazar, Juan Diego MD; Nahar, Bryan Lester MD; Jim, Belinda MD. Finerenone: A Novel Third-Generation Mineralocorticoid Receptor Antagonist. Cardiology in Review. 2023. https://doi.org/10.1097/CRD.0000000000000573 .</Citation></Reference><Reference><Citation>Yang P, Shen W, Chen X, Zhu D, Xu X, Wu T, et al. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24:637&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pubmed">31030322</ArticleId><ArticleId IdType="doi">10.1007/s10741-019-09790-5</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty KF, Henderson AD, Jhund PS, Claggett BL, Desai AS, Mueller K, et al. Efficacy and safety of finerenone across the ejection fraction spectrum in heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the FINEARTS-HF trial. Circulation. 2025;151:45&#x2013;58.</Citation><ArticleIdList><ArticleId IdType="pubmed">39342512</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.124.072011</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>